



Strategies for replacing non-invasive brain stimulation sessions: recommendations for 




Introduction: Despite the potential impact of missed visits on the outcomes of neuromodulation 
treatments, it is not clear how this issue has been addressed in clinical trials. Given this gap in the 
literature, we reviewed articles on non-invasive brain stimulation in participants with depression 
or chronic pain, and investigated how missed visits were handled. 
Areas covered: We performed a search on PUBMED/MEDLINE using the keywords: “tDCS”, 
“transcranial direct current stimulation”, “transcranial magnetic stimulation¨, “depression”, and 
“pain”. We included studies with a minimum of five participants who were diagnosed with 
depression or chronic pain, who underwent a minimum of five tDCS or TMS sessions. A total of 
181 studies matched our inclusion criteria, 112 on depression and 69 on chronic pain. Of these, 
only fifteen (8%) articles reported or had a protocol addressing missed visits. This review 
demonstrates that, in most of the trials, there is no reported plan to handle missed visits. 
Expert commentary: Based on our findings and previous studies, we developed suggestions on 
how to handle missed visits in neuromodulation protocols. A maximum of 20% of missing 
sessions should be allowed before excluding a patient and these sessions should be replaced at 
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Transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation 
(TMS) use electrical or magnetic current to modulate neural excitability and brain plasticity [1]. 
These non-invasive brain stimulation techniques (NIBS) have been shown to improve 
depression’s symptoms, pain, as well as motor and cognitive deficits [2–5]. From a clinical 
perspective, to achieve persisting behavioral effects, participants should attend multiple 
neurostimulation visits [6,7]. However, daily visits can be burdensome and might promote low 
adherence. This decreased adherence is costly, affect intervention’s effectiveness, and biases the 
final potential positive results of an intervention [8–10]. Various strategies to improve adherence 
exist, yet there are very few established approaches once a neurostimulation visit is missed [8,9].  
 To study how missed neurostimulation visits are managed, we reviewed randomized 
clinical trials (RCT) that used tDCS and TMS to treat depression and chronic pain. We first 
selected depression and we wanted to confront our results with another condition to explore if 
the issue of missed visits was exclusive of depressive syndromes or may be generalized to other 
conditions. We selected these conditions since they are highly prevalent and commonly 
associated with poor adherence (e.g. missed visits)  [11,12]. In addition, these disorders are 
frequently studied in neurostimulation trials which have shown promising results for symptom 
reduction (for reviews see [13–17]). Based on our findings, we proposed a strategy to handle 




We searched PUBMED/MEDLINE for clinical trials published before 2017, using the 
keywords: “tDCS”, “transcranial direct current stimulation”, “transcranial magnetic stimulation¨, 
“depression”, and “pain”. Two different searches were performed to reduce the chances to 
exclude eligible articles. The exact highly sensitive search strategy [18], can be found in 
supplementary table 1.  
Once the search was performed, we extracted the data and perform of first screening 
based on the titles and abstracts. Inclusion criteria were:  i) Papers written in English; ii) A 
minimum of 5 tDCS or TMS sessions; iii) A sample size ≥5 participants; iv) Studies on 
depression or chronic pain. Exclusion criteria were: i) Case reports and case series; ii) Follow-up 
studies; iii) Observational studies; iv) Articles using the same sample but with different 
endpoints (only the first published trial was included); v) Animals studies.  
For the articles that matched our inclusion and exclusion criteria, a full-text review was 
done and, if no further exclusion criteria were identified, a quantitative analysis of each article 
was performed. 
This systematic review did not involve human subjects. We only reviewed published articles and 
data published in these articles. As reviews and meta‐analyses do not involve human subjects, 
they do not require IRB review [19]. 
Results 
3.1 Depression  
 In total, we extracted 1136 articles that used tDCS and TMS for the treatment of 
depression. Of these, 112 (fifteen on tDCS and ninety-seven on TMS) matched our 
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inclusion/exclusion criteria and were further quantitatively analyzed (Figure 1). After a 
systematic review of these 112 papers, 9 mentioned missed visits in their protocol. Details 
regarding each study protocol are reported in Tables 1 and 2. 
Findings’ summary 
Three out of fifteen articles on tDCS reported the occurrence of missed neurostimulation visits 
[7,20]. Brunoni et al. (2013) defined participants who missed three or more consecutive 
neurostimulation visits out of 12 (25% of missed visits) as drop-outs [7]. These participants were 
excluded from statistical analyses. Not excluded from analysis were the 103 participants that 
completed the intervention, where 41 finished all sessions, 37 had one absence and 25 had two. 
In the other article, Brunoni et al. (2014) randomized 37 participants, and had 21 dropouts [20]. 
Even though the same dropout rule was used, the amount that dropped due to missed 
neurostimulation visit(s) was not specified. Vanderhasselt et al. (2015) used the same threshold 
of two consecutive missing sessions, in such cases extra tDCS sessions were performed to 
complete the total number of sessions [21]. The exact number of patients who missed one or 
more sessions was not reported. Concerning RCTs on TMS, five articles out of 97 detailed the 
possibility for patients to miss one or more sessions in their methodology and one article 
reported missed visits as a reason for dropout in the study flowchart. George et al. (2010) defined 
completers as patients having less than 4 rescheduled, missed or partially completed sessions, 
and fully adherent as patients having a maximum of 1 rescheduled, missed, or partially complete 
sessions (n=15 sessions) [23]. Out of 190 patients, 120 were fully adherent (63%) and 154 were 
considered as completers (81%). In another trial, George et al. (2014) defined true completers as 
patients receiving all treatment sessions with the entire number of pulses, even though this was 
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an inpatients study [24]. 27 out of 41 patients were considered as true completers (66%), 9 did 
not receive the full treatment (22%) and 5 dropped-out (12%). The authors found that the decline 
in suicidal thinking was more pronounced in the completers group. In another study by Leuchter 
et al. (2015), participants underwent 30 TMS sessions (5 per week for 6 weeks) [26]. A 
maximum of six missed neurostimulation visits was used to define dropout (20% of missed 
visits). Patients who did not complete 80% of the scheduled sessions were excluded from the 
analysis (67 out of 202 patients). They also demonstrated that participants needed to receive at 
least 80% of the rTMS doses (24 out of 30 sessions) to have a statistically significant 
antidepressant effect. However, neither the rational nor the numbers of dropouts were reported, 
and replacement of the missed neurostimulation visits was not detailed. Blumberger et al. (2012) 
allowed a maximum of 2 consecutive sessions to be missed or 4 for the entire protocol consisting 
of 15 sessions [25]. 30 out of 74 patients did not completed the 6-week protocol; the reasons for 
drop-outs were not detailed. The same team allowed up to 1 missed session per week (20%) and 
these sessions were replaced at the end of the protocol [26]. However, the proportion of patients 
who missed one or more sessions was not described. Finally, Levkovitz et al. (2015) reported in 
the study flowchart that two participants were excluded from the study after missing two sessions 
[27]. No further details were described. 
3.2 Pain  
Overall, we extracted 473 articles that studied neurostimulation for the treatment of 
chronic pain. From these 473 articles, 69 (35 on tDCS and 34 on TMS) matched our criteria and 
were systematically reviewed (Figure 2).  After our quantitative analysis, we only identified 3 
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articles (4%) mentioning strategies to manage missed neurostimulation visits. The information 
regarding each study protocol is detailed in tables 3 and 4. 
Findings’ summary: 
For tDCS, Auvichayapat et al. (2012) and Castillo-Saavedra et al. (2016) withdrew participants 
when they missed a single neurostimulation visit [28], while Fagerlund et al. (2015) withdrew 
only after two or more neurostimulation  visits were missed [29]. These visits were never 
replaced.  
Out of the 34 trials on TMS, only two of them mentioned management of missed 
neurostimulation visits. Ambriz-Tutut et al. (2016) removed a subject due to “poor compliance”, 
however they do not explicitly describe their definition of adherence [30]. Malavera et al. (2016) 
excluded participants that missed one or more day(s) of stimulation [31].  
Discussion 
According to the Health World Organization, adherence is defined as, "the extent to 
which a person's behavior - taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a health care provider” [32], while no 
specific cut-off for good or poor adherence has been defined yet. Despite the apparent prevalence 
in clinical research, there is no established gold standard to manage missed visits.  
Our analysis of 181 papers revealed that missed visits are widely underreported in NIBS 
RCTs on depression and chronic pain, since less than 10% of the trials (n=15) mentioned this 
issue. More precisely, in depression, 8% of the trials reported missed visits and most of them 
how they managed this issue, while for pain, only 4% of trial did report missed visit but did not 
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provide any further details on how to handle this problem. In studies detailing missing visits, the 
rate of patients who were not fully adherent is extremely high, ranging from 30 to 60%, 
reflecting the importance of taking this factor into account when designing a trial and when 
reporting the results.  
 Herein, we discuss the importance of missed visit(s) and provide recommendations 
regarding potential methods to deal with this issue based on the current literature of tDCS and 
TMS. To do this, we discussed the following questions: (i) When should missed visit(s) be 
considered a protocol violation and the participant excluded?; (ii) Should missed 
neurostimulation visit(s) be replaced at the end of the stimulation period?; (iii) When do missed 
neurostimulation visits bias results?  
(i) When should (and if) missed visits be considered protocol violation and the 
participant excluded? 
Although it is well-defined that multiple sessions of tDCS and TMS have cumulative effects, the 
impact of spaced sessions in abolishing, potentiating or having no effect still needs to be further 
clarified [16,33–35].  This was explored by Zanão et al. (2014), based on their previous trial [36] 
where some patients did not attend all visit [37].  They showed that missing one or two tDCS 
visits (out of 10) did not alter the treatment effectiveness [37]. Likewise, Leuchter et al. (2015), 
demonstrated that participants needed to receive at least 80% of the rTMS doses (24 out of 30 
sessions) to have a statistically significant antidepressant effect [26].  In addition, George et al. 
(2014) reported that patients receiving the full treatment demonstrated higher improvement in 
their symptoms as compared to non-completers [24].  
9 
 
The results from Zanão et al (2014) and Leuchter et al (2015) reflect pharmacological 
trials’ guidelines, in which poor adherence is frequently considered as less than 80% of 
medication taken correctly [38]. Regardless, there is no universally accepted definition of 
adequate adherence, despite its potential impact on treatment effectiveness [39]. For instance, if 
aspirin is taken once a month, it does not prevent myocardial infarction (3% adherence, 1/30 
days), while, when it is taken once a week, it can help decreasing the incidence of myocardial 
infarction (14% adherence, 4/30 days). These properties are summarized in different models by 
Kravitz et al (2014).  In linear and curvilinear models, the percent of benefit increases as 
adherence increases. In ON-OFF models, benefit is only achieved when adherence nears 100%. 
Finally, in threshold models, benefit is limited below a certain point and maximal above that 
point [40]. As such, minimum adherence expectations should reflect an intervention’s properties 
and trials’ objectives.  Under the assumption that tDCS and TMS efficacy follows Kravitz´s 
models, guaranteeing that the participant receives a sufficient treatment dose to maximize the 
outcome is relevant [40–43]. Therefore, based on the reviewed literature, in these populations, 
and in NIBS trials with at least 5 or more stimulation visits, it seems reasonable to allow up to 
20% of neurostimulation visits to be missed.  
 (ii)   Should missed visit(s) be replaced at the end of the stimulation period?  
Regarding the studies on tDCS in depression, missed neurostimulation visits were only 
replaced at the end of the treatment period in three trials [7,20,21]. In Brunoni et al. (2013), only 
about 40% of the participants received the full intervention as designed, while about 60% had at 
least one session replaced at the end of the treatment period [7]. Replacement of visits had no 
impact on the final results as long as the participants were adherent to 80% of the intervention. 
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To ensure treatment efficacy and that all participants received the same number of treatment 
sessions, it may be favorable to replace missed visits at the end of the designated stimulation 
period. In addition, the replacement sessions allow for a more flexible schedule, which could 
promote increased adherence and reduce the number of dropouts. In order to have a good balance 
between the flexibility required when working with participants with depression and chronic 
pain, and the mandatory rigor for RCTs, an additional interval (e.g. 1 week) could be included in 
the protocol to account for the replacement of missed visits at the end of the planned stimulations 
session.  
To support this recommendation – replacing missing sessions at the end of the 
stimulation period – one of the trials included in this review compared the efficacy of rTMS 
when applied every day (5 days per week) for 4 weeks, with rTMS applied every other day (3 
days per week) [44] for 6 weeks. After 4 weeks, participants in the daily treatment group, who 
had received 20 sessions, showed more improvement than participants in the spaced treatment 
group, who had received 12 sessions, showing the importance of the number of treatments 
sessions given to induce a significant clinical effect. However, at the end of the 6-week period, 
once the spaced treatment group had accrued the total 18 sessions, the outcomes were 
statistically comparable between the two groups (5 days per week vs 3 days per week).  The 
results of this study reflect that spacing the treatments with one day intervals, had no effect on 
treatment efficacy if the entire number of sessions were provided, which support our 
recommendation to replace the missed visit at the end of the stimulation period.  
In future RCTs, a comparison between the impact of replaced sessions versus non-
replaced session on treatment effectiveness could be a valuable approach to understand this 
11 
 
dosing issue. Using the analysis of Leuchter et al (2015) as a model [26], researchers could 
compare data collected under per-protocol analysis, to intention to treat analysis and replaced 
session analysis. This would help to assess the impact of missed visits on clinical outcomes and 
to find cut-off points for poor adherence. 
 (iii) When do missed neurostimulation visits bias final results? 
Many drug trials report on the effects of poor adherence with a negative impact on the 
outcomes. For instance, in a multicentric RCT including more than 1000 participants with 
coronary heart disease, the authors identified a significant difference in term of complications 
between participants with an adherence of more or less than 75% [45]. They reported that 
nonadherence (i.e., <75%) was associated with a greater rate of subsequent cardiovascular 
events, up to two times more than in participants with good adherence (i.e., >75%). In other 
trials, the threshold is slightly different (e.g., 80% [38]). 
Based on the BCM – Bienenstock, Cooper, and Munro – and metaplasticity theories, it 
can be mentioned that the effects of long-term potentiation (LTP) and long-term depression 
(LTD) are limited and after a certain number of interventions no further neuroplastic changes are 
expected [46,47]. With neurostimulation, hyperactive neurons reduce input by increasing their 
thresholds (LTP to LTD) while hypoactive neurons do the opposite (LTD to LTP) [47]. This 
parallels pharmacologic dosing, and drug half-lives, and is a window into understanding dosing 
mechanisms in NIBS.  Briefly, these physiological considerations may support the results seen in 
George et al. (2010), Brunoni et al (2013), Zanão et al (2014) and Leuchter et al (2015). For this 





In future RCTs using neurostimulation, it is important to detail both the timing of missed 
visit(s) and how this issue was handled when reporting the results. Concerning the impact of 
missed neuromodulation visits, it would be interesting to compare the results of participants who 
did not miss any visits versus participants who missed one, two or more visits, if the sample is 
large enough. This might help researchers and clinicians to understand how missed visits could 
affect the results and how many treatment sessions could be missed without impacting the 
outcome. Based on the current literature, allowing 20% of missed visits, while replacing these 
sessions at the end of the designated stimulation period, seems to be a valuable balance between 
the rigor requested by RCTs and the expected clinical translation. It also seems to be beneficial 
as a method to decrease results bias of this important question.  
 Our review shows that missed visits are an important issue that has not been adequately 
addressed in neurostimulation RCTs in depression and chronic pain. A better understanding of 
the impact of missed neurostimulation appointments is essential to avoid erroneous conclusions 
on its efficacy. This will help scientists and clinicians to understand the genuine impact of non-
adherence and establish better strategies that optimize participants’ engagement in their 
treatment.  
Expert commentary: Missed visits are common in neurostimulation trials especially in 
populations with poor adherence such as depression and chronic pain. In the present review, we 
noticed that most RCTs did not report missed visits and less than 10% of the RCTs reviewed 
clearly stated how these missed visits were managed when they occurred. We proposed a plan to 
handle this issue by allowing up to 20% of appointments to be missed and replacing those visits 
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at the end of the designated stimulations period as successfully done in several RCTs 
[20,21,27,48]. This method seems to have an appropriate balance between the rigor required in 
RCT and the flexibility needed for patients with depression or chronic pain, or other conditions 
inclined to missed treatment visits. On the other hand, we have found evidence that 20% of 
missed neurostimulation visits may not impact the clinical results [37]. However, nothing is 
known about the possible impact on the long-term effects of this treatment since the neuroplastic 
strengthening would not have been as strong as if patients would have received daily stimulation 
sessions. Future RCTs assessing the effect of 20%, or more, of missed visit need to be conducted 
including long-term assessments (e.g., 6 months). In our opinion, the duration of the effects is 
another important point to take into account. 
 One current limitation of tDCS and TMS use is their unfeasibility to be applied at home, 
thus, requiring patients to go to laboratories or hospital every day to receive these treatments, 
which could increase the probability of missing sessions. Therefore, an option to improve 
adherence to neurostimulation treatments is the development of home-based devices.  
We hope that this review will encourage researchers to develop plans to handle missed 
visits in their protocol and to clearly detail this issue when reporting the results. In addition, we 
expect that future RCTs comparing different proportions of  missed visits on direct and long-
lasting effects, will help to answer this critical question “how many missed neurostimulation 
visits will impact the clinical results?” It is essential to tackle this question to facilitate the 
clinical translation of neurostimulation treatments.  
Five Year View 
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Within the next five years we believe that device trials will develop a clearer understanding of 
dose-response curves in relation to tDCS and TMS. We expect there to be a minimum and 
maximum tolerated doses tailored and required per condition. With the development of clinical 
trials aiming to investigate NIBS dose-response, we will be able to predict the effects of not 
attending a neurostimulation visit. This will change the interpretation of attrition on outcomes, 
and statistical methods to handle missing data. It will also create new strategies for administering 
NIBS and offer new protocol designs options (e.g., allowing one or more missed visit) that might 
be closer to what is feasible in clinical practice.   
Key issues:  
 Missed neurostimulation visits occur in non-invasive brain stimulation clinical research. 
 There is no standardized method for dealing with missed neurostimulation visits. Some 
trials exclude the participants immediately, others allow for a predetermined amount of 
absentee to occur.  
 We have found published evidence that 20% of missed neurostimulation visits may be an 
allowable quantity of absentee, to maintain effects of NIBS.  
 However, the long-term effects of missed visits is yet to be determined, and therefore it 
can be better to replace the missed neurostimulation visit at the end of the 
neurostimulation period to ensure that all participants receive the same dose of NIBS in a 
clinical trial.  
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Figure 1: Flow chart for missed visits in depression.  
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